TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: For patients with PTCL, CD30 testing results are not available in claims data; however, most patients with PTCL retreated with BV in this study had a subtype (i.e., sALCL or PTCL-NOS) with a CD30 expression rate of ≥60% [12].